ATP2A3

Across TCGA pan-cancer cohorts, ATP2A3 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATP2A3 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ATP2A3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP2A3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

LUSC, UCEC, and BRCA are the cancer types where ATP2A3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	28	view →
UCEC	DFS	Median	All	0.941	0.826	.023	18	view →
BRCA	OS	Median	III,IV	0.027	0.907	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
HNSC	OS	Median	All	0.490	0.769	.019	6	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATP2A3–LUSC (DFS)

Open the LUSC breakdown →